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Abstract. Clinical isolates of Leishmania, from visceral leishmaniasis (VL) cases in Nepal and from cutaneous
leishmaniasis (CL) cases in Peru, were cultured using polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) to type species and strain. Promastigotes from 38 isolates, within eight passages from isolation, were
used to infect mouse peritoneal macrophage cultures in vitro, and the amastigote sensitivity to miltefosine was deter-
mined. The concentration required to kill 50% of intracellular amastigotes from Nepalese VL isolates, all typed as
Leishmania (L.) donovani (N  24) from both Sbv responders and nonresponders, ranged from 8.7 to 0.04 g/mL. In
contrast, the concentration required to kill 50% intracellular amastigotes from isolates from Peru, typed as L.(V.)
braziliensis (N  8), was > 30 to 8.4 g/mL, L.(V.) guyanensis (N  2) > 30 to 1.9 g/mL, L.(L.) mexicana (N  1) >
30 g/mL, and L. (V.) lainsoni (N  4) was 3.4 to 1.9 g/mL. This demonstrates a notable difference in the intrinsic
sensitivity of Leishmania species to miltefosine in vitro. If this model can be correlated to therapeutic outcome, it may
have implications for the interpretation of clinical trials.
INTRODUCTION
The current chemotherapy for leishmaniasis is limited. Pen-
tavalent antimonials have been the recommended drugs for
the treatment of both visceral (VL) and cutaneous leishma-
niasis (CL) for more than 50 years, but long courses, toxicity,
and resistance in India limit their use. New drugs have be-
come available in recent years for the treatment of both VL,
including highly efficacious but expensive lipid amphotericin
B formulations, of which AmBisome is the only one widely
available. Oral miltefosine has recently been licensed for use
in India for the treatment of VL. Topical formulations of
paromomycin and oral miltefosine have been used to treat CL.1
Miltefosine is an alkylphosphocholine, initially developed
as an anticancer agent, that also shows selective activity
against Leishmania.2 Miltefosine has undergone successful
clinical trials for anthroponotic VL in Bihar state, India, with
94% cure rate, including antimony-resistant cases,3 and is cur-
rently in Phase IV trials in India and Nepal. This oral drug has
demonstrated some activity in the treatment of zoonotic CL
in South America4,5 where it is currently in Phase III clinical
trials.6 There are more than 17 species of Leishmania that
cause leishmaniasis in human populations; these species have
been shown to vary in sensitivity to a range of anti-
leishmanial drugs7 including miltefosine.8 The current study is
the first to evaluate the in vitro anti-leishmanial activity of
miltefosine against recently isolated, typed Leishmania spp.
from patients in the Old and New Worlds.
MATERIALS AND METHODS
Ethical clearance was obtained from the ethical committees
of the Health Research Council, Kathmandu, Nepal, and
Cayetano Heredia University, Lima, Peru. Patients were re-
cruited to the study from November 2002 until the beginning
of 2004. Clinical cases of VL in Nepal were recruited at the B
P Koirala Institute of Health Sciences, Dharan, Nepal, from a
catchment area covering the eastern Terai. Individuals less
than 2 years old were excluded from the study. Suspected VL
cases, fever for 14 days or longer with splenomegaly, were
confirmed by bone marrow aspiration and visual identifica-
tion of parasites. All patients received 20 mg SbV kg−1 day−1
intramuscularly for 30 days (sodium antimony gluconate; Al-
bert David Ltd, Calcutta, India). Unresponsive patients sub-
sequently received amphotericin B (amphotericin B deoxy-
cholate) treatment.
Cutaneous leishmaniasis patients were recruited at the In-
stituto Alexander von Humbolt, Lima, Peru, with geographi-
cal location noted in the patient data (Table 1). Pregnant
women were excluded from the study. Patients presenting
with an ulcerated or nodular lesion were considered. Infec-
tion by Leishmania was confirmed by direct examination of
punch biopsy material with confirmation by parasite culture
or PCR. Patients received 20 mg SbV kg−1 day−1 intrave-
nously for 20 days, except for PER069 who received treat-
ment of 30 days. Unresponsive patients received a repeat
course of antimonials. If this was again unsuccessful, patients
received intravenous amphotericin B (amphotericin B deoxy-
cholate).
Patient material was isolated directly onto 3N9 blood slopes
with a saline/antibiotic overlay and sent to ITG, Antwerp.
Parasites were cryopreserved in aliquots and typed within
eight passages from isolation. Frozen stocks were sent to
LSHTM, London, where the parasites were passaged initially
onto 3N slopes with M199 + 20% HIFCS overlay, then into
M199 + 20% HIFCS alone. It was necessary to introduce the
use of M19910 to obtain a clean, bulk culture of promastigotes
that would be sufficient for further evaluation. There is some
evidence that the type of medium can affect the infectivity of
the parasite,11 however, in this study all isolates were exposed
to exactly the same growth conditions, and the work was
carried out as close to the isolation as possible. Standard op-
erating procedures were established between partners, which
would minimize the effect of this variable between the strains.
The parasites were tested for their in vitro sensitivity to milte-
fosine within eight passages from isolation.
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Late stage promastigotes were used to infect primary iso-
lated mouse peritoneal macrophages at a ratio of 7 promas-
tigotes to 1 macrophage in Labtek 16-well tissue culture well
slides (VWR Ltd, Poole, UK), in quadruplicate. Infected cul-
tures were maintained in RPMI 1640 medium (Sigma, Gill-
ingham, UK) with 10% heat-inactivated fetal calf serum
(Harlan SeraLab, Loughborough, UK) at 37°C (VL strains)
or 34°C (CL strains) in a 5% CO2/95% air mixture. Twenty-
four hours after infection, one slide was methanol-fixed and
Giemsa-stained to determine the initial level of infection. Cul-
tures were then exposed to miltefosine (hexadecylphospho-
choline, HPC; A G Scientific, San Diego, CA) over a dose
range of 30, 10, 3, and 1 g/mL, in quadruplicate at each
concentration. Higher concentrations were not tested due
toxicity to macrophage host cells: at concentrations above 30
g/mL, macrophages infected are destroyed and the slide
cannot be evaluated. After 5 days, all slides were methanol-
fixed and Giemsa-stained. The percent of infected macro-
phages in each well was determined by microscopy. From a
comparison of counts from treated with untreated cultures,
the percent inhibition was calculated by sigmoidal regression
analysis (MS xlfit) and ED50 (ED90) values determined.
Leishmania (V.) braziliensis MHOM/BR/75/M2903 was the
reference strain used for Peruvian isolates. L. (L.) donovani
MHOM/ET/67/HU3 was used as the reference strains for Ne-
palese isolates. Both strains are known as WHO reference
strains, as typed by isoenzyme analysis, and are sensitive to
the standard antimonials, sodium stibogluconate and meglu-
mine antimoniate.
Leishmania species typing. In Antwerp, Leishmania spe-
cies typing was performed by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
analysis of cysteine proteinase b (cpb) and gp63 genes for
Nepalese strains and by multi-locus PCR-RFLP for Peruvian
strains. Briefly, DNA was extracted from cultivated promas-
tigotes with the QIAmp DNA mini Kit (Qiagen, Hilden, Ger-
many), amplified and digested as reported elsewhere.12–14
Restriction patterns were resolved by capillary electrophore-
sis (2100 Bioanalyzer system, Agilent Technologies,
Karlsruhe, Germany) in a micro-chip device (LabChip 1500,
Caliper Technologies, Mountain View, CA) and compared
with those of reference strains. Standard strains were also
re-typed and confirmed to be L. (L.) donovani and L. (V.)
braziliensis.
RESULTS
The range of activity of miltefosine against South American
isolates of cutaneous leishmaniasis is shown in Table 1. L. (V.)
lainsoni (PER105) was the most sensitive strain tested with an
ED50 value of 1.89 g/mL. L. (V.) braziliensis and L. (V.)
guyanensis isolates were insensitive to miltefosine over the
range tested (30–0.3 g/mL). The only isolates, for example
PER127, which showed sensitivity to miltefosine were typed
as L. (V.) lainsoni, with ED50 values ranging from 3.37 to 1.89
g/mL.
The activity of miltefosine against VL isolates from Nepal
is shown in Table 2 with ED50 values ranging from less than
0.04 g/mL to 8 g/mL. Results were similar in repeated
experiments. Although the strains were identified as two L.
(L.) donovani types (I and II, based on restriction pattern
differences),12,14,15 there was no significant difference in sen-
sitivity to miltefosine between them. The differences seen in
the RFLP pattern are useful when tracing the genetic rela-
tionships among the strains. L. (L.) donovani HU3 is an
Ethiopian strain of VL maintained in passage animals. An
Indian reference strain would perhaps have been a more ap-
propriate comparator but was not available to us at the time
of this study.
DISCUSSION
This study supports previous work comparing species sen-
sitivity to miltefosine, which found significant differences be-
tween New World and Old World CL and demonstrated sig-
TABLE 1
Sensitivity of Peruvian cutaneous leishmaniasis isolates to miltefosine
Species ID
ED50 ± SEM g miltefosine/mL
(ED90 ± SEM)
Patient details
(Age; M/F)
Region
(Department)
Clinical response to
antimonial treatment¶
PER010 > 30 (> 30)
L. (V.) braziliensis PER012* > 30 (> 30) 32; M Cusco Nonresponder
L. (V.) braziliensis PER014 > 30 (> 30) 14; M Junin Nonresponder
L. (V.) braziliensis PER067 28.3 (> 30) 23 M Cusco Nonresponder
L. (V.) braziliensis PER122 21.3 ± 2.5 (19.7 ± 2.4) 35; M Madre de Dios Responder
L. (V.) braziliensis PER016 > 30 (> 30) 22; M Huanaco Initial cure
L. (V.) braziliensis PER069† 22.2 (> 30) 47; M Madre de Dios Nonresponder/relapse
L. (V.) braziliensis PER010 > 30 (> 30) 22; F Cajamarca Initial cure
L. (V.) guyanensis PER054 > 30 (> 30) 29; F Junin Unknown‡
L. (V.) guyanensis PER132 8.4 ± 2.22 (14.42 ± 4.3) 65; M Junin Definite cure
L. (V.) lainsoni PER092 3.37 ± 0.1 (4.02 ± 0.25) 33; M Junin Initial cure
L. (V. lainsoni PER105 1.89 ± 0.17 (3.51 ± 0.22) 13; M Madre de Dios Responder
L. (V.) lainsoni PER 127 3.1 ± 0.94 (> 30) 9; M San Martin Responder
L. (V.) lainsoni PER131 2.4 ± 0.22 (4.42 ± 0.43) 20; M Junin Initial cure
PER068 > 30 (> 30)
L. (L) mexicana PER068 > 30 10; M Ayacucho Unknown‡
L. (V) braziliensis M2903§ – – –
* Isolate taken after completion of antimonial treatment.
† Mucosal leishmaniasis.
‡ Patients lost to follow-up.
§ M2903 is WHO reference strain L. (V.) braziliensis MHOM/BR/75/M2903.
¶ Initial cure—resolution of clinical signs and symptoms at 1 month. Currently in 6-month follow-up period. Definite cure—complete resolution of cllinical signs and symptoms with no evidence
of relapse at 6, 12, and 24 months after treatment.
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nificantly different sensitivities between New World species.8
This report, one of the few that includes both molecular typ-
ing and sensitivity studies of a large number of recent isolates
from patients, reflecting results seen in a recent clinical trial of
miltefosine against cutaneous leishmaniasis.5 That study con-
cluded that miltefosine, at 2.5 mg kg−1 day−1, had comparable
efficacy to antimonials when treating presumed L. (V.) pana-
mensis in Colombia, less so against presumed L. (V.) bra-
ziliensis in Guatemala, but needed further evaluation against
more endemic species. Earlier studies have described differ-
ences in the sensitivity of species and strains of Leishmania to
antimonials, azoles, allopurinol, and paromomycin (see Ref.
7). Six laboratory-maintained isolates of Leishmania have
also shown variation in sensitivity to miltefosine. In a 3-day
amastigote-macrophage assay, ED50 values ranged from 2.6
to 37.7 M (1–15.4 g/mL), L. (L.) donovani and L.(L.) aethi-
opica being the most sensitive species and L. (L.) major the
least sensitive.8 In that study, the ED50 values of L. (L.) mexi-
cana and L. (V.) panamensis were reported as 6.8–10.1 (2.8–
4.1 g/mL) and 10.6 M (4.3 g/mL), respectively. The re-
sults presented in this paper on 38 clinical isolates also indi-
cate that L. (L.) donovani is intrinsically sensitive to
miltefosine. In contrast, most of the isolates typed to the L.
(V.) braziliensis complex were insensitive with the exception
of those identified as L. (V.) lainsoni.
As with in vitro sensitivity to antimonials and other anti-
leishmanial drugs, there appears to be intrinsic variation in
species sensitivity to miltefosine. If this is reflected in vivo this
has important implications for the evaluation of clinical trials
of the drug in Latin America. A dosing regimen of miltefosine
at 2.5 mg kg−1 day−1 (150 mg of drug) for 28 days was required
to have a significant effect against Colombian L. (V.) pana-
mensis but was not as effective against Guatemalan L. (V.)
braziliensis.5 It should be noted that the species were identi-
fied by historical data in these studies. The evidence suggests
that miltefosine may be a useful drug for the treatment of
South American CL, however, species identification should
perhaps be a priority before treatment to give the best chance
of efficacy and to reduce the possibility of either encouraging
resistance to develop, a potential problem when considering
anthroponotic transmission, or by re-enforcing intrinsic drug
insensitivity, as may be the case in zoonotic foci. Resistance
mechanisms to miltefosine been identified in laboratory-
induced Leishmania.16,17 It would be interesting to see if
these were present in unresponsive “wild-type” parasites.
The utility of the in vitro test when assessing isolate drug
sensitivity could be improved by testing parasites pre- and
post-treatment, but, to date, the number of samples where
this is possible is not significant. Finally, the relevance of in
vitro data to clinical outcome must also be considered as the
two parameters may not necessarily correlate—confounding
factors such as host immunity are absent from these tests.18
The data serve to emphasize the extremely complex clinical
picture of leishmaniasis.
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TABLE 2
Sensitivity of Nepalese visceral leishmaniasis isolates to miltefosine
Species ID
ED50 ± SEM g miltefosine/mL
(ED90 ± SEM)
Patient details
(Age; M/F)
Region
(District)§
Clinical response
to antimonial treatment¶
L. donovani (I)
L. donovani (I) BPK025/0 0.5 ± 0.2 (0.9 ± 0.07) 32; M Sunsari Definite cure
L. donovani (II) BPK026/0 1.9 ± 0.6 (6.9 ± 0.8) 48; M Bhojpur Definite cure
L. donovani (I) BPK035/0 1.32 ± 0.09 (2.5 ± 0.21) 9; M Saptari Nonresponder
L. donovani (I) BPK043/0 1.0 ± 0.04 (2.2 ± 0.1) 10; M Sunsari Definite cure
L. donovani (II) BPK077/0† 5.6 ± 0.7 (13.5 ± 1.5) 40; M Saptari Nonresponder
L. (L.) donovani (I) BPK080/0 1.2 ± 0.1 (3.3 ± 0.2) 36; F Sunsari Relapse
L. (L.) donovani (I) BPK085/0 5.6 ± 0.6 (10.0 ± 2.2) 32; M Saptari Definite cure
L. (L.) donovani (I) BPK087/0 5.6 ± 0.6 (10.1 ± 2.7) 40; M Morang Definite cure
L. (L.) donovani (I) BPK090/0 4.9 ± 0.2 (7.4 ± 0.5) 46; M Sunsari Definite cure
L. (L.) donovani (I) BPK091/0 1.9 ± 0.06 (6.9 ± 0.8) 40; M Sunsari Definite cure
L. (L.) donovani (I) BPK164/1† 2.2 ± 0.1 (8.2 ± 1.3) 40; M Dhanusa Nonresponder
L. (L.) donovani (I) BPK177/0† 8.1 ± 0.06 (0.9 ± 0.2) 40; M Dhanusa Relapse
L. (L.) donovani (I) BPK178/0 5.7 ± 0.7 (12.6 ± 0.6) 45; M Sunsari Initial cure
L. (L.) donovani (I) BPK190/0 0.9 ± 0.2 (7.3 ± 4.0) 10; M Morang Nonresponder
L. (L.) donovani (I) BPK191/0 2.0 ± 0.1 (5.8 ± 0.8) 16; F Morang Initial cure
L. (L.) donovani (I) BPK192/0 2.0 ± 0.2 (4.1 ± 0.5) 7; F Morang Initial cure
L. (L.) donovani (I) BPK206/0 3.9 ± 1.6 (10.2 ± 3.2) 12; M Morang Initial cure
L. (L.) donovani (I) BPK208/0‡ 0.04 ± 0.02 (1.7 ± 0.9) 20; F Morang Initial cure
L. (L.) donovani (I) BPK212/0 3.2 ± 0.3 (6.3 ± 1.1) 50; M Sunsari Initial cure
L. (L.) donovani (I) BPK274/0 0.85 ± 0.14 (4.0 ± 0.5) 18; F Sunsari Initial cure
L. (L.) donovani (I) BPK275/0 1.03 ± 0.04 (2.6 ± 0.2) 12; F Morang Nonresponder
L. (L.) donovani (I) BPK276/0 0.2 ± 0.1 (2.4 ± 0.7) 10; F Sunsari Initial cure
L. (L.) donovani (I) BKP278/0 2.2 ± 0.2 (8.8 ± 1.3) 7; F Morang Initial cure
L. (L.) donovani (I) BPK279/0 0.09 ± 0.73 (1.18 ± 0.2) 10; M Morang Initial cure
L. (L.) donovani HU3* 8.7 ± 0.6 (25.7 ± 2.6) – –
* HU3 is WHO reference strain L. donovani MHOM/ET/67/HU3.
† Isolates taken after completion of antimonial treatment.
‡ Pregnant patient treated with amphotericin B.
§ All districts are on the southeastern border of Nepal.
¶ Initial cure—resolution of clinical symptoms 6 months after treatment, negative bone marrow aspirate. Currently in follow-up period. Definite cure—complete resolution of clinical signs and
symptoms with no evidence of relapse 12 months after treatment, negative bone marrow aspirate.
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